8th Global Pharmacovigilance and Drug safety summit

Follow
Verify
From Verify.Wiki
Jump to: navigation, search
QuickUpload1085 20170613012414.png
8th Global Pharmacovigilance and Drug safety summit
Date July 06-07, 2017
Place Kuala Lumpur, Malaysia
With the grand success of Pharmacovigilance Series of Conferences in UK, USA in consecutive years over the last several years which met with great achievement in Business Conferencing.   

Announcing 8th Global Pharmacovigilance & Drug Safety Summit during July 6-7, 2017 in Kuala Lumpur, Malaysia with the theme “Innovations in Pharmacovigilance for Systematic safety and Management”.This is a 2 day Mega Event offering Exhibition, at venue to showcase the new and emerging technologies with Keynote presentation, Oral, YRF (Student Presentation), poster, e-poster Presentations.

About Conference[1]

ConferenceSeries Ltd organizes a conference series of 1000+ Global Events inclusive of 1000+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

With the grand success of Pharmacovigilance Series of Conferences in UK, USA in consecutive years over the last several years which met with great achievement in Business Conferencing. Announcing 8th Global Pharmacovigilance & Drug Safety Summit during July 6-7, 2017 in Kuala Lumpur, Malaysia with the theme “Innovations in Pharmacovigilance for Systematic safety and Management”. 

Drug Safety

Concept of drug safety is also known as Medication Safety in the field of health. It is associated with adverse effects of Pharmaceutical products involving many other scientific aspects, such as the side effects of drugs, the quality of medications, medication error in usage of drugs, lack of efficacy of drugs, and counterfeit drugs. Patient Safety, Drug Interaction (drug–drug and food–drug interaction) Drug Pharmacokinetic, and Adverse Drug Reaction are several terms involved with Drug Safety. Companies have to conduct a complete drug safety and pharmacovigilance audit to gauge their compliance with international standards of laws, regulations, and guidance.

In this track we will be focusing on Drug Safety Updates, Drug Safety Solutions, Training, Surveillance, Services & Software, Reporting & Monitoring.

Main Target of this Conference [1]

8th Global Pharmacovigilance & Drug Safety Summit emphasizes on how the importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence various sectors.

The field of Pharmacovigilance is growing day by day and its development is marking high impact in fields of Pharmaceuticals and Medical Sciences. This conference creates a global platform to reach the largest assemblage of participants from various sectors to share their insights and convey recent developments in the field of Medicinal sciences, Health care and Drug Discovery involving Pharmacovigilance studies, Risk Management and Safety of Drug. This is a true forum where ideas and discussion is driven by the participants and interaction with peers and others leads to fruitful outcomes.

Why to attend:

This Conference stand out and attract attendees by creating value for all Attendees to learn, to network and meet people, inspired, solicit business and  to glance attractive places in Malaysia. Conduct presentations, distribute information, meet with current and potential Pharmacovigilance/Drug Safety Experts, make a splash with new drug developments, and receive name & fame.

Targeted Audience:[1]

Pharmacovigilance and Drug Safety Officers, Senior Pharmacovigilance Regulators and Inspectors,

CRO and Consultants providing QPPV Services,

Regulatory Affairs Officers,

Local Medicines Authorities,

Clinical Risk-Benefit Groups,

Pharma Industry Directors,

Heads and Managers of  Compliance,

Drug Safety Officers,

Global Drug Safety Officers,

Heads of Safety and Pharmacovigilance,

Inspection and Audit,

International PV Auditors,

Lead Safety Scientists,

Medical Affairs,

Patient Safety,

Pharmacoepidemiology Pharmacovigilance,

Consultants,

Pharmacovigilance Managers,

Pharmacovigilance Team Leaders,

PSMF,

PV Quality System,

QPPV Personnel’s,

Regulatory Affairs Managers,

Safety & Risk management Safety.

Market Analysis[1]

Global Pharmacovigilance Market is expected to reach USD 5.51 billion by 2020, according to a new study by Grand View Research, Inc. Increasing incidence rates of adverse drug reaction and the introduction of stringent drug safety regulations are some key drivers of this market. ADR is responsible for approximately 5% of the hospitalization in developed countries annually, and this is expected to boost usage rates over the next six years. Pharmacovigilance has witnessed a significant rise in usage rates in the recent times owing to growing global geriatric population triggering a growth in demand for new drug development. Additionally, health regulatory authorities such as the U.S. FDA and EMEA (European Medicines Agency) are now emphasizing on electronic submission of data which is also expected to drive the pharmacovigilance market.

Contract outsourcing pharmacovigilance market is expected to grow at a lucrative rate of over 13.1% during the forecast period. Service flexibility and cost effectiveness associated with outsourcing are some key factors accounting for the segment’s lucrative growth.

Further key findings from the study suggest: Global Pharmacovigilance Market is expected to reach USD 5.51 billion by 2020, according to a new study by Grand View Research, Inc. Increasing incidence rates of adverse drug reaction and the introduction of stringent drug safety regulations are some key drivers of this market. ADR is responsible for approximately 5% of the hospitalization in developed countries annually, and this is expected to boost usage rates over the next six years. Pharmacovigilance has witnessed a significant rise in usage rates in the recent times owing to growing global geriatric population triggering a growth in demand for new drug development. Additionally, health regulatory authorities such as the U.S. FDA and EMEA (European Medicines Agency) are now emphasizing on electronic submission of data which is also expected to drive the pharmacovigilance market.

Contract outsourcing pharmacovigilance market is expected to grow at a lucrative rate of over 13.1% during the forecast period. Service flexibility and cost effectiveness associated with outsourcing are some key factors accounting for the segment’s lucrative growth.

  • Pharmacovigilance services found the largest application in phase 4/IV clinical trial studies in 2013. Greater applicability and relevance are some factors accounting for the segment’s market position.
  • Contract outsourcing was the most revenue generating service provider segment in 2013. Minimization of upfront investments and reduction in fixed overhead costs are some factors expected to drive segment growth.
  • North America was the largest regional market, accounting for over 40.0% of the revenue in 2013. Presence of stringent healthcare regulations implemented by the U.S. FDA and high market penetration rates of electronic medical records are some factors responsible for its large share.  
  • Asia Pacific is identified as the most lucrative market. Presence of a large pool of skilled labor and favorable business environments are some factors expected to drive regional market growth. Rapidly improving healthcare infrastructure in the emerging economies of India and China is also expected to provide new growth opportunities to the market participants.
  • Key players of this market include Quintiles Transnational Corporation, PAREXEL International, Clinquest Group BV, Pharmaceutical Product Development, Accenture Plc., Boehringer Ingelheim GmbH and Cognizant Technology Solutions
  • Providing customized end to end PV solutions & services and entering into strategic agreements are some key strategies adopted by these market players. 

References

  1. 1.0 1.1 1.2 1.3 http://globalpharmacovigilance.pharmaceuticalconferences.com/
 

Verification history